aluates Reports

$ 0.0

Automative

Global Constrained Peptide Drugs Market Research Report 2025

Published Date: March 2025

Report Code: QYRE-Auto-37O9861

Global Constrained Peptide Drugs Market Research Report 2022

BUY CHAPTERS

Global Constrained Peptide Drugs Market Research Report 2025

Code: QYRE-Auto-37O9861

Report

March 2025

Pages:87

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Aileron Therapeutics Inc

Polyphor

Protagonist Therapeutics Inc

PeptiDream

Creative Peptides

Bio-Synthesis, Inc.

Bicycle Therapeutics, PLC

Santhera Pharmaceuticals Holding

Union Chimique Belge S.A. (UCB)

Pepscan Therapeutics B.V.

Pepticom Ltd.

CPC Scientific Inc.

Constrained Peptide Drugs Market Size

The global market for Constrained Peptide Drugs was valued at US$ 406 million in the year 2024 and is projected to reach a revised size of US$ 619 million by 2031, growing at a CAGR of 6.3% during the forecast period.

Constrained Peptide Drugs Market

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Constrained Peptide Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Constrained Peptide Drugs.

The Constrained Peptide Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Constrained Peptide Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Constrained Peptide Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Constrained Peptide Drugs Market Report

Report Metric	Details
Report Name	Constrained Peptide Drugs Market
Accounted market size in year	US$ 406 million
Forecasted market size in 2031	US$ 619 million
CAGR	6.3%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Cyclic Peptides Disulfide-Rich Peptides (DRPs)
Segment by Application	Hospital Institute of Biology Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Aileron Therapeutics, Inc, Bicycle Therapeutics, PLC, Polyphor Limited, Protagonist Therapeutics, Inc, Santhera Pharmaceuticals Holding, Union Chimique Belge S.A. (UCB), Pepscan Therapeutics B.V., Pepticom Ltd., PeptiDream, Inc., CPC Scientific Inc., Creative Peptides, Bio-Synthesis Inc
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Constrained Peptide Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Constrained Peptide Drugs Market growing?

Ans: The Constrained Peptide Drugs Market witnessing a CAGR of 6.3% during the forecast period 2025-2031.

What is the Constrained Peptide Drugs Market size in 2031?

Ans: The Constrained Peptide Drugs Market size in 2031 will be US$ 619 million.

Who are the main players in the Constrained Peptide Drugs Market report?

Ans: The main players in the Constrained Peptide Drugs Market are Aileron Therapeutics, Inc, Bicycle Therapeutics, PLC, Polyphor Limited, Protagonist Therapeutics, Inc, Santhera Pharmaceuticals Holding, Union Chimique Belge S.A. (UCB), Pepscan Therapeutics B.V., Pepticom Ltd., PeptiDream, Inc., CPC Scientific Inc., Creative Peptides, Bio-Synthesis Inc

What are the Application segmentation covered in the Constrained Peptide Drugs Market report?

Ans: The Applications covered in the Constrained Peptide Drugs Market report are Hospital, Institute of Biology, Others

What are the Type segmentation covered in the Constrained Peptide Drugs Market report?

Ans: The Types covered in the Constrained Peptide Drugs Market report are Cyclic Peptides, Disulfide-Rich Peptides (DRPs)

Recommended Reports

Pharmaceutical Drugs

Drug Discovery & Development

Pharma Services & Supply

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Constrained Peptide Drugs Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Cyclic Peptides

1.2.3 Disulfide-Rich Peptides (DRPs)

1.3 Market by Application

1.3.1 Global Constrained Peptide Drugs Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Hospital

1.3.3 Institute of Biology

1.3.4 Others

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Constrained Peptide Drugs Market Perspective (2020-2031)

2.2 Global Constrained Peptide Drugs Growth Trends by Region

2.2.1 Global Constrained Peptide Drugs Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Constrained Peptide Drugs Historic Market Size by Region (2020-2025)

2.2.3 Constrained Peptide Drugs Forecasted Market Size by Region (2026-2031)

2.3 Constrained Peptide Drugs Market Dynamics

2.3.1 Constrained Peptide Drugs Industry Trends

2.3.2 Constrained Peptide Drugs Market Drivers

2.3.3 Constrained Peptide Drugs Market Challenges

2.3.4 Constrained Peptide Drugs Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Constrained Peptide Drugs Players by Revenue

3.1.1 Global Top Constrained Peptide Drugs Players by Revenue (2020-2025)

3.1.2 Global Constrained Peptide Drugs Revenue Market Share by Players (2020-2025)

3.2 Global Constrained Peptide Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Constrained Peptide Drugs Revenue

3.4 Global Constrained Peptide Drugs Market Concentration Ratio

3.4.1 Global Constrained Peptide Drugs Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Constrained Peptide Drugs Revenue in 2024

3.5 Global Key Players of Constrained Peptide Drugs Head office and Area Served

3.6 Global Key Players of Constrained Peptide Drugs, Product and Application

3.7 Global Key Players of Constrained Peptide Drugs, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Constrained Peptide Drugs Breakdown Data by Type

4.1 Global Constrained Peptide Drugs Historic Market Size by Type (2020-2025)

4.2 Global Constrained Peptide Drugs Forecasted Market Size by Type (2026-2031)

5 Constrained Peptide Drugs Breakdown Data by Application

5.1 Global Constrained Peptide Drugs Historic Market Size by Application (2020-2025)

5.2 Global Constrained Peptide Drugs Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Constrained Peptide Drugs Market Size (2020-2031)

6.2 North America Constrained Peptide Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Constrained Peptide Drugs Market Size by Country (2020-2025)

6.4 North America Constrained Peptide Drugs Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Constrained Peptide Drugs Market Size (2020-2031)

7.2 Europe Constrained Peptide Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Constrained Peptide Drugs Market Size by Country (2020-2025)

7.4 Europe Constrained Peptide Drugs Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Constrained Peptide Drugs Market Size (2020-2031)

8.2 Asia-Pacific Constrained Peptide Drugs Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Constrained Peptide Drugs Market Size by Region (2020-2025)

8.4 Asia-Pacific Constrained Peptide Drugs Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Constrained Peptide Drugs Market Size (2020-2031)

9.2 Latin America Constrained Peptide Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Constrained Peptide Drugs Market Size by Country (2020-2025)

9.4 Latin America Constrained Peptide Drugs Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Constrained Peptide Drugs Market Size (2020-2031)

10.2 Middle East & Africa Constrained Peptide Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Constrained Peptide Drugs Market Size by Country (2020-2025)

10.4 Middle East & Africa Constrained Peptide Drugs Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Aileron Therapeutics, Inc

11.1.1 Aileron Therapeutics, Inc Company Details

11.1.2 Aileron Therapeutics, Inc Business Overview

11.1.3 Aileron Therapeutics, Inc Constrained Peptide Drugs Introduction

11.1.4 Aileron Therapeutics, Inc Revenue in Constrained Peptide Drugs Business (2020-2025)

11.1.5 Aileron Therapeutics, Inc Recent Development

11.2 Bicycle Therapeutics, PLC

11.2.1 Bicycle Therapeutics, PLC Company Details

11.2.2 Bicycle Therapeutics, PLC Business Overview

11.2.3 Bicycle Therapeutics, PLC Constrained Peptide Drugs Introduction

11.2.4 Bicycle Therapeutics, PLC Revenue in Constrained Peptide Drugs Business (2020-2025)

11.2.5 Bicycle Therapeutics, PLC Recent Development

11.3 Polyphor Limited

11.3.1 Polyphor Limited Company Details

11.3.2 Polyphor Limited Business Overview

11.3.3 Polyphor Limited Constrained Peptide Drugs Introduction

11.3.4 Polyphor Limited Revenue in Constrained Peptide Drugs Business (2020-2025)

11.3.5 Polyphor Limited Recent Development

11.4 Protagonist Therapeutics, Inc

11.4.1 Protagonist Therapeutics, Inc Company Details

11.4.2 Protagonist Therapeutics, Inc Business Overview

11.4.3 Protagonist Therapeutics, Inc Constrained Peptide Drugs Introduction

11.4.4 Protagonist Therapeutics, Inc Revenue in Constrained Peptide Drugs Business (2020-2025)

11.4.5 Protagonist Therapeutics, Inc Recent Development

11.5 Santhera Pharmaceuticals Holding

11.5.1 Santhera Pharmaceuticals Holding Company Details

11.5.2 Santhera Pharmaceuticals Holding Business Overview

11.5.3 Santhera Pharmaceuticals Holding Constrained Peptide Drugs Introduction

11.5.4 Santhera Pharmaceuticals Holding Revenue in Constrained Peptide Drugs Business (2020-2025)

11.5.5 Santhera Pharmaceuticals Holding Recent Development

11.6 Union Chimique Belge S.A. (UCB)

11.6.1 Union Chimique Belge S.A. (UCB) Company Details

11.6.2 Union Chimique Belge S.A. (UCB) Business Overview

11.6.3 Union Chimique Belge S.A. (UCB) Constrained Peptide Drugs Introduction

11.6.4 Union Chimique Belge S.A. (UCB) Revenue in Constrained Peptide Drugs Business (2020-2025)

11.6.5 Union Chimique Belge S.A. (UCB) Recent Development

11.7 Pepscan Therapeutics B.V.

11.7.1 Pepscan Therapeutics B.V. Company Details

11.7.2 Pepscan Therapeutics B.V. Business Overview

11.7.3 Pepscan Therapeutics B.V. Constrained Peptide Drugs Introduction

11.7.4 Pepscan Therapeutics B.V. Revenue in Constrained Peptide Drugs Business (2020-2025)

11.7.5 Pepscan Therapeutics B.V. Recent Development

11.8 Pepticom Ltd.

11.8.1 Pepticom Ltd. Company Details

11.8.2 Pepticom Ltd. Business Overview

11.8.3 Pepticom Ltd. Constrained Peptide Drugs Introduction

11.8.4 Pepticom Ltd. Revenue in Constrained Peptide Drugs Business (2020-2025)

11.8.5 Pepticom Ltd. Recent Development

11.9 PeptiDream, Inc.

11.9.1 PeptiDream, Inc. Company Details

11.9.2 PeptiDream, Inc. Business Overview

11.9.3 PeptiDream, Inc. Constrained Peptide Drugs Introduction

11.9.4 PeptiDream, Inc. Revenue in Constrained Peptide Drugs Business (2020-2025)

11.9.5 PeptiDream, Inc. Recent Development

11.10 CPC Scientific Inc.

11.10.1 CPC Scientific Inc. Company Details

11.10.2 CPC Scientific Inc. Business Overview

11.10.3 CPC Scientific Inc. Constrained Peptide Drugs Introduction

11.10.4 CPC Scientific Inc. Revenue in Constrained Peptide Drugs Business (2020-2025)

11.10.5 CPC Scientific Inc. Recent Development

11.11 Creative Peptides

11.11.1 Creative Peptides Company Details

11.11.2 Creative Peptides Business Overview

11.11.3 Creative Peptides Constrained Peptide Drugs Introduction

11.11.4 Creative Peptides Revenue in Constrained Peptide Drugs Business (2020-2025)

11.11.5 Creative Peptides Recent Development

11.12 Bio-Synthesis Inc

11.12.1 Bio-Synthesis Inc Company Details

11.12.2 Bio-Synthesis Inc Business Overview

11.12.3 Bio-Synthesis Inc Constrained Peptide Drugs Introduction

11.12.4 Bio-Synthesis Inc Revenue in Constrained Peptide Drugs Business (2020-2025)

11.12.5 Bio-Synthesis Inc Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Aileron Therapeutics Inc

Polyphor

Protagonist Therapeutics Inc

PeptiDream

Creative Peptides

Bio-Synthesis, Inc.

Bicycle Therapeutics, PLC

Santhera Pharmaceuticals Holding

Union Chimique Belge S.A. (UCB)

Pepscan Therapeutics B.V.

Pepticom Ltd.

CPC Scientific Inc.

List of Tables

Table 1. Global Constrained Peptide Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Cyclic Peptides

Table 3. Key Players of Disulfide-Rich Peptides (DRPs)

Table 4. Global Constrained Peptide Drugs Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 5. Global Constrained Peptide Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 6. Global Constrained Peptide Drugs Market Size by Region (2020-2025) & (US$ Million)

Table 7. Global Constrained Peptide Drugs Market Share by Region (2020-2025)

Table 8. Global Constrained Peptide Drugs Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 9. Global Constrained Peptide Drugs Market Share by Region (2026-2031)

Table 10. Constrained Peptide Drugs Market Trends

Table 11. Constrained Peptide Drugs Market Drivers

Table 12. Constrained Peptide Drugs Market Challenges

Table 13. Constrained Peptide Drugs Market Restraints

Table 14. Global Constrained Peptide Drugs Revenue by Players (2020-2025) & (US$ Million)

Table 15. Global Constrained Peptide Drugs Market Share by Players (2020-2025)

Table 16. Global Top Constrained Peptide Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Constrained Peptide Drugs as of 2024)

Table 17. Ranking of Global Top Constrained Peptide Drugs Companies by Revenue (US$ Million) in 2024

Table 18. Global 5 Largest Players Market Share by Constrained Peptide Drugs Revenue (CR5 and HHI) & (2020-2025)

Table 19. Global Key Players of Constrained Peptide Drugs, Headquarters and Area Served

Table 20. Global Key Players of Constrained Peptide Drugs, Product and Application

Table 21. Global Key Players of Constrained Peptide Drugs, Date of Enter into This Industry

Table 22. Mergers & Acquisitions, Expansion Plans

Table 23. Global Constrained Peptide Drugs Market Size by Type (2020-2025) & (US$ Million)

Table 24. Global Constrained Peptide Drugs Revenue Market Share by Type (2020-2025)

Table 25. Global Constrained Peptide Drugs Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 26. Global Constrained Peptide Drugs Revenue Market Share by Type (2026-2031)

Table 27. Global Constrained Peptide Drugs Market Size by Application (2020-2025) & (US$ Million)

Table 28. Global Constrained Peptide Drugs Revenue Market Share by Application (2020-2025)

Table 29. Global Constrained Peptide Drugs Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 30. Global Constrained Peptide Drugs Revenue Market Share by Application (2026-2031)

Table 31. North America Constrained Peptide Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 32. North America Constrained Peptide Drugs Market Size by Country (2020-2025) & (US$ Million)

Table 33. North America Constrained Peptide Drugs Market Size by Country (2026-2031) & (US$ Million)

Table 34. Europe Constrained Peptide Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 35. Europe Constrained Peptide Drugs Market Size by Country (2020-2025) & (US$ Million)

Table 36. Europe Constrained Peptide Drugs Market Size by Country (2026-2031) & (US$ Million)

Table 37. Asia-Pacific Constrained Peptide Drugs Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 38. Asia-Pacific Constrained Peptide Drugs Market Size by Region (2020-2025) & (US$ Million)

Table 39. Asia-Pacific Constrained Peptide Drugs Market Size by Region (2026-2031) & (US$ Million)

Table 40. Latin America Constrained Peptide Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 41. Latin America Constrained Peptide Drugs Market Size by Country (2020-2025) & (US$ Million)

Table 42. Latin America Constrained Peptide Drugs Market Size by Country (2026-2031) & (US$ Million)

Table 43. Middle East & Africa Constrained Peptide Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 44. Middle East & Africa Constrained Peptide Drugs Market Size by Country (2020-2025) & (US$ Million)

Table 45. Middle East & Africa Constrained Peptide Drugs Market Size by Country (2026-2031) & (US$ Million)

Table 46. Aileron Therapeutics, Inc Company Details

Table 47. Aileron Therapeutics, Inc Business Overview

Table 48. Aileron Therapeutics, Inc Constrained Peptide Drugs Product

Table 49. Aileron Therapeutics, Inc Revenue in Constrained Peptide Drugs Business (2020-2025) & (US$ Million)

Table 50. Aileron Therapeutics, Inc Recent Development

Table 51. Bicycle Therapeutics, PLC Company Details

Table 52. Bicycle Therapeutics, PLC Business Overview

Table 53. Bicycle Therapeutics, PLC Constrained Peptide Drugs Product

Table 54. Bicycle Therapeutics, PLC Revenue in Constrained Peptide Drugs Business (2020-2025) & (US$ Million)

Table 55. Bicycle Therapeutics, PLC Recent Development

Table 56. Polyphor Limited Company Details

Table 57. Polyphor Limited Business Overview

Table 58. Polyphor Limited Constrained Peptide Drugs Product

Table 59. Polyphor Limited Revenue in Constrained Peptide Drugs Business (2020-2025) & (US$ Million)

Table 60. Polyphor Limited Recent Development

Table 61. Protagonist Therapeutics, Inc Company Details

Table 62. Protagonist Therapeutics, Inc Business Overview

Table 63. Protagonist Therapeutics, Inc Constrained Peptide Drugs Product

Table 64. Protagonist Therapeutics, Inc Revenue in Constrained Peptide Drugs Business (2020-2025) & (US$ Million)

Table 65. Protagonist Therapeutics, Inc Recent Development

Table 66. Santhera Pharmaceuticals Holding Company Details

Table 67. Santhera Pharmaceuticals Holding Business Overview

Table 68. Santhera Pharmaceuticals Holding Constrained Peptide Drugs Product

Table 69. Santhera Pharmaceuticals Holding Revenue in Constrained Peptide Drugs Business (2020-2025) & (US$ Million)

Table 70. Santhera Pharmaceuticals Holding Recent Development

Table 71. Union Chimique Belge S.A. (UCB) Company Details

Table 72. Union Chimique Belge S.A. (UCB) Business Overview

Table 73. Union Chimique Belge S.A. (UCB) Constrained Peptide Drugs Product

Table 74. Union Chimique Belge S.A. (UCB) Revenue in Constrained Peptide Drugs Business (2020-2025) & (US$ Million)

Table 75. Union Chimique Belge S.A. (UCB) Recent Development

Table 76. Pepscan Therapeutics B.V. Company Details

Table 77. Pepscan Therapeutics B.V. Business Overview

Table 78. Pepscan Therapeutics B.V. Constrained Peptide Drugs Product

Table 79. Pepscan Therapeutics B.V. Revenue in Constrained Peptide Drugs Business (2020-2025) & (US$ Million)

Table 80. Pepscan Therapeutics B.V. Recent Development

Table 81. Pepticom Ltd. Company Details

Table 82. Pepticom Ltd. Business Overview

Table 83. Pepticom Ltd. Constrained Peptide Drugs Product

Table 84. Pepticom Ltd. Revenue in Constrained Peptide Drugs Business (2020-2025) & (US$ Million)

Table 85. Pepticom Ltd. Recent Development

Table 86. PeptiDream, Inc. Company Details

Table 87. PeptiDream, Inc. Business Overview

Table 88. PeptiDream, Inc. Constrained Peptide Drugs Product

Table 89. PeptiDream, Inc. Revenue in Constrained Peptide Drugs Business (2020-2025) & (US$ Million)

Table 90. PeptiDream, Inc. Recent Development

Table 91. CPC Scientific Inc. Company Details

Table 92. CPC Scientific Inc. Business Overview

Table 93. CPC Scientific Inc. Constrained Peptide Drugs Product

Table 94. CPC Scientific Inc. Revenue in Constrained Peptide Drugs Business (2020-2025) & (US$ Million)

Table 95. CPC Scientific Inc. Recent Development

Table 96. Creative Peptides Company Details

Table 97. Creative Peptides Business Overview

Table 98. Creative Peptides Constrained Peptide Drugs Product

Table 99. Creative Peptides Revenue in Constrained Peptide Drugs Business (2020-2025) & (US$ Million)

Table 100. Creative Peptides Recent Development

Table 101. Bio-Synthesis Inc Company Details

Table 102. Bio-Synthesis Inc Business Overview

Table 103. Bio-Synthesis Inc Constrained Peptide Drugs Product

Table 104. Bio-Synthesis Inc Revenue in Constrained Peptide Drugs Business (2020-2025) & (US$ Million)

Table 105. Bio-Synthesis Inc Recent Development

Table 106. Research Programs/Design for This Report

Table 107. Key Data Information from Secondary Sources

Table 108. Key Data Information from Primary Sources

Table 109. Authors List of This Report

List of Figures

Figure 1. Constrained Peptide Drugs Picture

Figure 2. Global Constrained Peptide Drugs Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Constrained Peptide Drugs Market Share by Type: 2024 VS 2031

Figure 4. Cyclic Peptides Features

Figure 5. Disulfide-Rich Peptides (DRPs) Features

Figure 6. Global Constrained Peptide Drugs Market Size by Application (2020-2031) & (US$ Million)

Figure 7. Global Constrained Peptide Drugs Market Share by Application: 2024 VS 2031

Figure 8. Hospital Case Studies

Figure 9. Institute of Biology Case Studies

Figure 10. Others Case Studies

Figure 11. Constrained Peptide Drugs Report Years Considered

Figure 12. Global Constrained Peptide Drugs Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 13. Global Constrained Peptide Drugs Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 14. Global Constrained Peptide Drugs Market Share by Region: 2024 VS 2031

Figure 15. Global Constrained Peptide Drugs Market Share by Players in 2024

Figure 16. Global Top Constrained Peptide Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Constrained Peptide Drugs as of 2024)

Figure 17. The Top 10 and 5 Players Market Share by Constrained Peptide Drugs Revenue in 2024

Figure 18. North America Constrained Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 19. North America Constrained Peptide Drugs Market Share by Country (2020-2031)

Figure 20. United States Constrained Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 21. Canada Constrained Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 22. Europe Constrained Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 23. Europe Constrained Peptide Drugs Market Share by Country (2020-2031)

Figure 24. Germany Constrained Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 25. France Constrained Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. U.K. Constrained Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. Italy Constrained Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. Russia Constrained Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. Nordic Countries Constrained Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Asia-Pacific Constrained Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Asia-Pacific Constrained Peptide Drugs Market Share by Region (2020-2031)

Figure 32. China Constrained Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. Japan Constrained Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. South Korea Constrained Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. Southeast Asia Constrained Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. India Constrained Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. Australia Constrained Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. Latin America Constrained Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Latin America Constrained Peptide Drugs Market Share by Country (2020-2031)

Figure 40. Mexico Constrained Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. Brazil Constrained Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Middle East & Africa Constrained Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Middle East & Africa Constrained Peptide Drugs Market Share by Country (2020-2031)

Figure 44. Turkey Constrained Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. Saudi Arabia Constrained Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. UAE Constrained Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. Aileron Therapeutics, Inc Revenue Growth Rate in Constrained Peptide Drugs Business (2020-2025)

Figure 48. Bicycle Therapeutics, PLC Revenue Growth Rate in Constrained Peptide Drugs Business (2020-2025)

Figure 49. Polyphor Limited Revenue Growth Rate in Constrained Peptide Drugs Business (2020-2025)

Figure 50. Protagonist Therapeutics, Inc Revenue Growth Rate in Constrained Peptide Drugs Business (2020-2025)

Figure 51. Santhera Pharmaceuticals Holding Revenue Growth Rate in Constrained Peptide Drugs Business (2020-2025)

Figure 52. Union Chimique Belge S.A. (UCB) Revenue Growth Rate in Constrained Peptide Drugs Business (2020-2025)

Figure 53. Pepscan Therapeutics B.V. Revenue Growth Rate in Constrained Peptide Drugs Business (2020-2025)

Figure 54. Pepticom Ltd. Revenue Growth Rate in Constrained Peptide Drugs Business (2020-2025)

Figure 55. PeptiDream, Inc. Revenue Growth Rate in Constrained Peptide Drugs Business (2020-2025)

Figure 56. CPC Scientific Inc. Revenue Growth Rate in Constrained Peptide Drugs Business (2020-2025)

Figure 57. Creative Peptides Revenue Growth Rate in Constrained Peptide Drugs Business (2020-2025)

Figure 58. Bio-Synthesis Inc Revenue Growth Rate in Constrained Peptide Drugs Business (2020-2025)

Figure 59. Bottom-up and Top-down Approaches for This Report

Figure 60. Data Triangulation

Figure 61. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Peptide Drug Conjugates Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Prescription Medicine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Super Generic Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Over the Counter Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Treatment Planning Software Market Research Report 2025

Global Diagnostic Guidewire Market Research Report 2024

Computer Vision in Pharmaceutical Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Coding and Marking for Pharmaceuticals and Consumer Products Market Research Report 2024

Digital Health and Digital Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Inspection System for Pharmaceutical Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Pharmerging Market Research Report 2025

Pharmaceutical Asset Managements Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Influenza Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Pharmaceutical Validation Services Market Research Report 2025

High density Multiplexed Diagnostic Assays Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global CGT Drugs Market Research Report 2025

Drug Delivery Technologies Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Pill Organizer with Timer Reminder Market Research Report 2025

Biopharma Cosmetics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

RELATED REPORTS

Global Pharma and Healthcare Social Media Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-14Y6812

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Food Additives Testing Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-34O3983

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Gabapentin API Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-9V17601

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Electronic Informed Consent Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-22C17047

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions